ArticleFrontiers in oncology2023

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.

Francesco Angotzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.